BiotechTube

Cadonilimab (AK104) + Oxaliplatin + Capecitabine + 5- Fluorouracil + Calcium Folinate

Phase 3Recruiting
0 watching 0 views this week๐Ÿ“ˆ Rising
76
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Resectable Colon Cancer

Conditions

Resectable Colon Cancer, MSI-H/dMMR Colorectal Cancer

Trial Timeline

Mar 15, 2026 โ†’ Mar 15, 2031

NCT ID
NCT07412613

About Cadonilimab (AK104) + Oxaliplatin + Capecitabine + 5- Fluorouracil + Calcium Folinate

Cadonilimab (AK104) + Oxaliplatin + Capecitabine + 5- Fluorouracil + Calcium Folinate is a phase 3 stage product being developed by Akeso for Resectable Colon Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07412613. Target conditions include Resectable Colon Cancer, MSI-H/dMMR Colorectal Cancer.

Hype Score Breakdown

Clinical
27
Activity
18
Company
9
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT07412613Phase 3Recruiting

Competing Products

20 competing products in Resectable Colon Cancer

See all competitors
ProductCompanyStageHype Score
[203Pb]VMT-ฮฑ-NET + [212Pb]VMT-ฮฑ-NETPerspective TherapeuticsPhase 1/2
33
ateganosine + CadonilimabMAIA BiotechnologyPhase 1
25
Trastuzumab deruxtecanDaiichi SankyoPre-clinical
23
PLX3397 + vemurafenibDaiichi SankyoPhase 1
33
Trastuzumab deruxtecanDaiichi SankyoPre-clinical
23
zolbetuximabAstellas PharmaPre-clinical
23
zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracilAstellas PharmaPhase 3
77
zolbetuximabAstellas PharmaPre-clinical
23
zolbetuximab + oxaliplatin + capecitabine + placeboAstellas PharmaPhase 3
77
zolbetuximab + Pembrolizumab + Capecitabine + Oxaliplatin + Folinic acid (leucovorin or local equivalent) + 5-fluorouracil (5-FU) + PlaceboAstellas PharmaPhase 3
77
ASP1948Astellas PharmaPhase 1
33
mFOLFOX7 combined with Camrelizumab and apatinibSun PharmaceuticalPhase 2
52
LenvatinibEisaiPhase 2
52
LenvatinibEisaiPhase 1
33
LenvatinibEisaiPhase 1/2
41
Nivolumab + EverolimusOno PharmaceuticalPhase 3
77
ONO-7913 + ONO-4538 + Fluorouracil + Oxaliplatin + Levofolinate + Bevacizumab + CetuximabOno PharmaceuticalPhase 1
33
SHR-4602Jiangsu Hengrui MedicinePhase 2
52
CamrelizumabJiangsu Hengrui MedicinePhase 3
77
SHR-1210 + Apatinib + SorafenibJiangsu Hengrui MedicinePhase 3
77

Other Products from Akeso

AK104(SC) + AK104(IV) + Capecitabine + Oxaliplatin injectionPhase 3
76
AK111 + AK111 + PlaceboPhase 3
76
AK104 + LenvatinibPhase 3
76
AK102 + AK102 + Placebo + PlaceboPhase 3
76
Penpulimab + placeboPhase 3
76